Shiva Saki
Biographic Data
| ID | 9008406 |
|---|---|
| NAME | Shiva Saki |
| GIVEN NAMES | Shiva |
| FAMILY NAME | Saki |
| SIGNATURE | SAKI S |
| AFFILIATIONS | Hamedan University of Medical Sciences |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome
BACKGROUND: receptor antagonist property. This study, therefore, was undertaken to investigate whether compared to placebo, mirtazapine would be efficacious and safe in the treatment of patients with IBS-D. METHODS: From November 2019 until July 2020, 67 patients meeting Rome IV criteria for IBS-D were randomized in a double-blind fashion into either the mirtazapine treatment group (n = 34) or the placebo treatment group (n = 33). Patients starte…
No prominent works on this page.
A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome
BACKGROUND: receptor antagonist property. This study, therefore, was undertaken to investigate whether compared to placebo, mirtazapine would be efficacious and safe in the treatment of patients with IBS-D. METHODS: From November 2019 until July 2020, 67 patients meeting Rome IV criteria for IBS-D were randomized in a double-blind fashion into either the mirtazapine treatment group (n = 34) or the placebo treatment group (n = 33). Patients starte…
Antidepressant (1 work) · Bloating (1 work) · Defecation (1 work) · Diarrhea (1 work) · Gastroenterology (1 work) · Gastrointestinal motility and disorders (1 work) · Inflammatory Bowel Disease (1 work) · Internal Medicine (1 work) · Irritable bowel syndrome (1 work) · Medicine (1 work)